XENE
Xenon Pharmaceuticals Inc. · Healthcare · Biotechnology
Input momentum (manajer yang sebanding): keluasan pemegang 0.0% · aliran saham +4.8% · posisi baru bersih 0.0% · formula
Semua angka kepemilikan: hanya manajer 13F yang dipantau, posisi saham biasa, periode pelaporan Q3 2025
| Kuartal | Pemegang | Δ | Saham | Nilai yang dilaporkan | Baru | Keluar |
|---|---|---|---|---|---|---|
| Q3 2026 | 1 | 0 | 130 | $5,069 | n/a | n/a |
| Q2 2026 | 113 | +7 | 55.63M | $3.35B | +11 | −5 |
| Q1 2026 | 110 | +12 | 59.13M | $3.41B | +18 | −6 |
| Q4 2025 | 96 | 0 | 51.65M | $2.31B | +1 | −1 |
| Q3 2025 | 17 | 0 | 29.02M | $1.17B | n/a | n/a |
| Q2 2025 | 14 | -1 | 23.81M | $745.12M | +1 | −2 |
| Q1 2025 | 12 | +1 | 10.74M | $360.22M | +1 | n/a |
| Q4 2024 | 11 | -1 | 10.24M | $401.45M | n/a | −1 |
| Q3 2024 | 11 | 0 | 11.68M | $459.86M | n/a | n/a |
| Q2 2024 | 11 | n/a | 11.68M | $455.36M | n/a | n/a |
| # | Manajer | Saham | Δ saham | Nilai | Bobotnya | Dipegang | ||
|---|---|---|---|---|---|---|---|---|
| 1 | Fidelity (FMR) ✦ | 8.92M | +0.4% | $358.09M | 0.0% | ▲ Add | 2 | SEC ↗ ×3 |
| 2 | BlackRock ✦ (pasif) | 4.77M | -11.1% | $191.55M | 0.0% | ▼ Trim | 2 | SEC ↗ ×13 |
| 3 | Wellington Management ✦ | 3.61M | +66.0% | $144.94M | 0.0% | ▲ Add | 6 | SEC ↗ ×7 |
| 4 | JPMorgan Chase ✦ | 2.80M | n/a | $112.34M | 0.0% | n/c | 1 | SEC ↗ ×16 |
| 5 | State Street Global Advisors ✦ (pasif) | 1.47M | +6.2% | $58.88M | 0.0% | ▲ Add | 4 | SEC ↗ |
| 6 | Millennium Management ✦ | 1.38M | +56.8% | $55.57M | 0.0% | ▲ Add | 6 | SEC ↗ |
| 7 | Geode Capital Management ✦ (pasif) | 977.43K | +0.7% | $39.24M | 0.0% | ▲ Add | 6 | SEC ↗ ×2 |
| 8 | Citadel Advisors ✦ | 959.10K | +699.0% | $38.51M | 0.0% | ▲ Add | 6 | SEC ↗ |
| 9 | The Vanguard Group ✦ (pasif) | 851.39K | -2.5% | $34.18M | 0.0% | ▼ Trim | 2 | SEC ↗ ×5 |
| 10 | Adage Capital Partners ✦ | 835.10K | -35.3% | $33.53M | 0.1% | ▼ Trim | 6 | SEC ↗ |
| 11 | Goldman Sachs Group ✦ | 720.66K | n/a | $28.93M | 0.0% | n/c | 1 | SEC ↗ ×3 |
| 12 | Capital World Investors ✦ | 655.74K | 0.0% | $26.33M | 0.0% | Held | 6 | SEC ↗ |
| 13 | Marshall Wace ✦ | 611.98K | -40.0% | $24.57M | 0.0% | ▼ Trim | 6 | SEC ↗ |
| 14 | Morgan Stanley ✦ | 366.57K | n/a | $14.72M | 0.0% | n/c | 1 | SEC ↗ ×9 |
| 15 | D. E. Shaw & Co. ✦ | 48.45K | -65.8% | $1.95M | 0.0% | ▼ Trim | 6 | SEC ↗ |
| 16 | T. Rowe Price ✦ | 41.69K | +9.9% | $1.68M | 0.0% | ▲ Add | 2 | SEC ↗ ×2 |
| 17 | Renaissance Technologies ✦ | 5.20K | -39.5% | $208,780 | 0.0% | ▼ Trim | 6 | SEC ↗ |
"Their weight" = porsi posisi dari nilai ekuitas 13F yang dilaporkan manajer tersebut: ukuran keyakinan. ✦ = manajer yang dikurasi.
Pembeli baru
| Tidak ada pembeli terlacak baru kuartal ini. |
Telah keluar
| Tidak ada keluar yang terlacak kuartal ini. |
Konteks pasar penuh: di SEMUA filer 13F (data terstruktur SEC, Q1 2026): 289 pemegang, 98.30M saham, $5.52B dilaporkan. Ini adalah periode berbeda yang lebih lama dibandingkan angka semesta yang dilacak di atas, dan keduanya tidak pernah dicampur.
Apa lagi yang paling sering dimiliki oleh pemegang sekuritas ini yang dilacak: jumlah kepemilikan bersama, bukan hubungan fundamental.
Pembelian di pasar terbuka (P)
Officer · Chief Financial… · 15.00K lbr @ 37.32 · $559,740
Officer, Director · PRESIDENT & CEO · 30.00K lbr @ 37.38 · $1.12M
Penjualan di pasar terbuka (S)
Officer · 6.37K lbr · $383,145
Officer · 700 lbr · $42,684
Director · 10.00K lbr · $640,550
Penghargaan, eksekusi, dan pemotongan pajak tidak pernah dihitung sebagai pembelian atau penjualan di sini. Metodologi